OTRIVIN Trademark

Trademark Overview

On Thursday, August 16, 2007, a trademark application was filed for OTRIVIN with the United States Patent and Trademark Office. The USPTO has given the OTRIVIN trademark a serial number of 77256552. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 10, 2011. This trademark is owned by Novartis AG. The OTRIVIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cough, cold and allergy symptoms
otrivin

General Information

Serial Number77256552
Word MarkOTRIVIN
Filing DateThursday, August 16, 2007
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 10, 2011
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 17, 2008

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cough, cold and allergy symptoms

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, August 20, 2007
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovartis AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBasel
CH
Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBasel
CH

Trademark Events

Event DateEvent Description
Tuesday, October 11, 2011ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, October 10, 2011ABANDONMENT - NO USE STATEMENT FILED
Tuesday, March 8, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 7, 2011EXTENSION 5 GRANTED
Thursday, March 3, 2011EXTENSION 5 FILED
Thursday, March 3, 2011TEAS EXTENSION RECEIVED
Wednesday, September 8, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 7, 2010EXTENSION 4 GRANTED
Thursday, September 2, 2010EXTENSION 4 FILED
Thursday, September 2, 2010TEAS EXTENSION RECEIVED
Thursday, March 11, 2010EXTENSION 3 GRANTED
Monday, March 8, 2010EXTENSION 3 FILED
Monday, March 8, 2010TEAS EXTENSION RECEIVED
Wednesday, September 9, 2009EXTENSION 2 GRANTED
Tuesday, September 8, 2009EXTENSION 2 FILED
Tuesday, September 8, 2009TEAS EXTENSION RECEIVED
Friday, May 1, 2009EXTENSION 1 GRANTED
Monday, March 9, 2009EXTENSION 1 FILED
Friday, May 1, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, April 14, 2009EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, April 14, 2009PETITION TO REVIVE-GRANTED
Tuesday, April 14, 2009TEAS PETITION TO REVIVE RECEIVED
Monday, April 13, 2009ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, April 13, 2009ABANDONMENT - NO USE STATEMENT FILED
Tuesday, September 9, 2008NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 17, 2008PUBLISHED FOR OPPOSITION
Wednesday, May 28, 2008NOTICE OF PUBLICATION
Friday, May 9, 2008LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, May 9, 2008ASSIGNED TO LIE
Thursday, May 8, 2008APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 8, 2008TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 8, 2008CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 8, 2008TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 22, 2008TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, November 15, 2007NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, November 15, 2007NON-FINAL ACTION E-MAILED
Thursday, November 15, 2007NON-FINAL ACTION WRITTEN
Thursday, November 15, 2007ASSIGNED TO EXAMINER
Monday, August 20, 2007NEW APPLICATION ENTERED IN TRAM

Related Keywords

otrivin allergy symptoms cold cough preparations treatment pharmaceutical